Failure to Monitor Drug Regimens and Side Effects
Summary
The facility failed to ensure that the drug regimens for three residents were free from unnecessary drugs by not adequately monitoring for side effects and adverse consequences. Resident 42 was prescribed Eliquis and clopidogrel for atrial fibrillation and gabapentin for epilepsy. However, there was no documentation of monitoring for signs and symptoms of bleeding and bruising associated with the use of Eliquis and clopidogrel, nor was there monitoring for signs of drug toxicity related to gabapentin. This lack of monitoring was noted in the resident's Medication Administration Record (MAR) for March 2025, despite the care plan indicating the need for such monitoring. Resident 79, who was prescribed atorvastatin for hyperlipidemia, did not have a lipid panel ordered or conducted since admission to the facility. The care plan for Resident 79 indicated the need to monitor the effect of the medication and perform laboratory work, but the clinical chart lacked any lipid laboratory results. This oversight was confirmed during an interview with a Licensed Vocational Nurse and the Director of Nursing, who acknowledged the importance of monitoring lipid levels to ensure the effectiveness of atorvastatin. Resident 40, who was on apixaban for deep vein thrombosis prophylaxis, did not have an order for monitoring adverse effects of the medication. The care plan highlighted the risk of adverse effects from this high-risk drug class, yet there was no monitoring for potential bleeding. The Director of Nursing confirmed that staff should have obtained an order for monitoring adverse effects and emphasized the importance of such monitoring to prevent complications. The facility's policies and procedures also underscored the need for monitoring adverse drug reactions and ensuring residents maintain the highest practicable level of functioning.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.